CAMBRIDGE, Mass. November 8, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to address obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that management...
–AD109 Achieved the Primary Endpoint of Reduced Nighttime Airway Obstruction –AD109 Significantly Improved Daytime Impairment Caused by OSA –AD109 Was Well-Tolerated CAMBRIDGE, Mass. October 17, 2022 – Apnimed, a clinical-stage pharmaceutical company...
CAMBRIDGE, Mass October 12, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to treat obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that company...
CAMBRIDGE, Mass. October 5, 2022 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that John Cronin, M.D., has joined the company as Senior Vice President, Clinical...
CAMBRIDGE, Mass. August 4, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, announced today the company will be participating in the upcoming...
– Additional Phase 2b data evaluating AD109 as potential treatment for OSA anticipated in Q3 2022 – AD109 Phase 3 development program expected to be initiated in late 2022 CAMBRIDGE, Mass. June 28, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on...
